FDA panel says Avastin should not be marketed for breast cancer treatment

Tuesday, July 20, 2010 - 20:49 in Health & Medicine

The recommendation does not affect the drug's marketing for treatment of four other types of cancer. New trials failed to confirm initial studies indicating some benefit for breast cancer patients. A Food and Drug Administration advisory committee Tuesday recommended that the agency withdraw its marketing approval of the blockbuster cancer drug Avastin for treating breast cancer, concluding that new trials showed no apparent...

Read the whole article on LA Times - Science

More from LA Times - Science

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net